tacrolimus
Term · Oncology and biomedicine · MLC-T-ONC-008488
A drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants.
A macrolide isolated from Streptomyces tsukubaensis. Tacrolimus binds to the FKBP-12 protein and forms a complex with calcium-dependent proteins, thereby inhibiting calcineurin phosphatase activity and resulting in decreased cytokine production. This agent exhibits potent immunosuppressive activity in vivo and prevents the activation of T lymphocytes in response to antigenic or mitogenic stimulation. Tacrolimus possesses similar immunosuppressive properties to cyclosporine, but is more potent.
| Identifier | MLC-T-ONC-008488 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | fujimycin |
| References | NCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-008488",
"term": "tacrolimus",
"field": "Oncology and biomedicine",
"definitions": [
"A drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants.",
"A macrolide isolated from Streptomyces tsukubaensis. Tacrolimus binds to the FKBP-12 protein and forms a complex with calcium-dependent proteins, thereby inhibiting calcineurin phosphatase activity and resulting in decreased cytokine production. This agent exhibits potent immunosuppressive activity in vivo and prevents the activation of T lymphocytes in response to antigenic or mitogenic stimulation. Tacrolimus possesses similar immunosuppressive properties to cyclosporine, but is more potent."
],
"synonyms": [
"fujimycin"
],
"references": [
"NCI Dictionary of Cancer Terms",
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/tacrolimus/"
}
Record 15,937 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.